CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Citius Pharmaceuticals, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.43−0.03 (-7.00%)
Close on Oct 19, 2026
- Market cap
- $11.20M
- P/E (TTM)
- –
- Dividend yield
- –
Citius Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $11.74M | $166.30M |
| Enterprise Value | $310.44M | $88.19M |
| PB Ratio | 0.18 | 2.03 |
| P/TBV Ratio | 0.21 | 2.29 |
Income (trailing twelve months)
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$38.53M | -$21.40M |
| Pretax Income | -$38.68M | -$14.34M |
| EBITDA | -$38.53M | -$16.91M |
| EPS (Diluted) | -$3.38 | -$0.83 |
Returns
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Return on Invested Capital (ROIC) | -8.51% | -32.4% |
| Return on Capital Employed (ROCE) | -42.5% | -38.1% |
Balance sheet
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $17.01M | $61.43M |
| Total Debt | $306.41M | $118.52M |
| Net Cash (Debt) | -$289.40M | $15.35M |
| Net Cash Per Share | -$10.54 | $0.66 |
| Equity (Book Value) | $66.61M | $49.09M |
| Book Value Per Share | $2.43 | $1.37 |
| Tangible Book Value | $57.27M | $23.52M |
| Working Capital | -$8.32M | $76.81M |
Financial position
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.84 | 3.34 |
| Quick Ratio | 0.34 | 2.44 |
| Debt / Equity | 4.60 | 0.52 |
| Interest Coverage | -143.87 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$26.55M | -$12.35M |
Efficiency
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Employee Count | 23 | 74 |
Dividends and yields
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Buyback Yield | -275.1% | -0.59% |
| Shareholder Yield | -275.1% | 0.00% |
Shares
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 27,452,600 | 58,127,000 |
| Shares Change (YoY) | 64.5% | 10.9% |
| Shares Change (QoQ) | 22.7% | 0.54% |
| Float | 26,544,000 | 49,136,700 |
| Shares Held by Insiders | 3.31% | 11.6% |
| Shares Held by Institutions | 4.96% | 59.4% |
Taxes
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $1.06M | $79.87K |
Scores
| Measure | Citius Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -3.58 | -0.22 |
Calculated by StockData from Citius Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.